http://rdf.ncbi.nlm.nih.gov/pubchem/patent/ES-2800066-T3
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_431309bc8dab94a0ee0e2aa5aeacd48d |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70503 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K2317-76 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-70546 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-505 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2333-7056 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6893 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2839 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-566 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-28 |
| filingDate | 2011-10-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_84af014ead6d3fe9dbc80a1d01b36221 |
| publicationDate | 2020-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | ES-2800066-T3 |
| titleOfInvention | Procedures to determine differences in alpha-4 integrin activity by correlating differences in sVCAM and / or sMAdCAM levels |
| abstract | An in vitro method for determining a difference in alpha-4 integrin activity in an individual with a disease or disorder selected from the group consisting of multiple sclerosis and inflammatory bowel disease, comprising: a) measuring a molecule soluble in a first biological sample of body fluid selected from the group consisting of blood, serum, and plasma and obtained from the individual immediately prior to administration of an alpha-4 integrin inhibitor; b) measuring the soluble molecule in a second biological sample, where the second biological sample is selected from the group consisting of blood, serum and plasma and has been obtained from the individual within thirty-one days after administration of the inhibitor of alpha-4 integrin; c) determine if there is a decrease in the levels of the soluble molecule between the first and the second biological sample, where the decrease is correlated with a decrease in the activity of alpha-4 integrin in the individual and, therefore, determine whether there is a difference in the activity of the alpha-4 integrin in the individual after the administration of the alpha-4 integrin inhibitor compared to before the administration of the alpha-4 integrin inhibitor; and d) determine if an adjustment in the treatment of the individual is required, where no decrease or a statistically insignificant decrease (p> 0.05) in the levels of the soluble molecule between the first and the second biological sample indicates an ineffective response to the inhibitor. of alpha-4 integrin that requires an individual's treatment adjustment, where the soluble molecule is sVCAM and / or sMAdCAM, and where the alpha-4 integrin inhibitor is an anti-alpha-4 integrin antibody. |
| priorityDate | 2010-10-25-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 344.